A trial of THR-317 in combination therapy with anti-VEGF treatments to treat diabetic macular edema.

Trial Profile

A trial of THR-317 in combination therapy with anti-VEGF treatments to treat diabetic macular edema.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs THR 317 (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2017 According to a ThromboGenics media release, results are expected during Q1 2018.
    • 10 Jul 2017 According to a BioInvent International media release, first patient was enrolled in Jan 2017.
    • 10 Jul 2017 Status changed from planning to recruiting,according to a BioInvent International media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top